Longitudinal Assessment of Cognitive Decline, Cerebrovascular Pathology, and Alzheimer's Disease Biomarkers in Elderly Individuals with Type 2 Diabetes Mellitus and Metabolic Syndrome

Pooja Menon, Dr. Sandeep Rao

Department of Geriatric Medicine and Translational Neuroscience, Madras Medical College (MMC)

1. Abstract

Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are increasingly acknowledged as significant factors in the development of neurodegenerative diseases, cognitive decline, and cerebrovascular issues among the elderly. The worldwide increase in dementia cases, especially Alzheimer's disease (AD), is occurring alongside the rising prevalence of T2DM and MetS, indicating common underlying mechanisms such as insulin resistance, vascular damage, chronic inflammation, oxidative stress, and disruptions in amyloid metabolism. Longitudinal research shows that those with T2DM and MetS experience faster cognitive deterioration, a higher likelihood of mild cognitive impairment (MCI), and a greater chance of progressing to dementia. Additionally, studies using neuroimaging and biomarkers have found links between blood sugar irregularities, tau pathology, neurodegeneration, and cerebrovascular issues, highlighting the necessity for comprehensive assessment models. This detailed research article offers a longitudinal framework for examining cognitive changes, cerebrovascular modifications, and AD-related biomarkers in older adults with T2DM and MetS. The review compiles evidence from epidemiological research, neuroimaging results, and molecular biomarker studies to clarify the pathophysiological connections between metabolic dysfunction and neurodegeneration. It also proposes a methodological strategy for longitudinal cohort evaluations that include cognitive assessments, neuroimaging techniques, and circulating biomarkers. The findings indicate that early metabolic issues predict worsening executive function, memory, and processing speed, along with structural brain changes like hippocampal shrinkage, white matter lesions, and decreased gray matter volume. Evidence also suggests that T2DM has a stronger link to neurodegeneration and tau pathology than to amyloid buildup. The article concludes that the combination of metabolic and cerebrovascular pathology speeds up AD-related cognitive decline in older populations. Early detection using integrated biomarker panels and ongoing monitoring could enhance risk assessment, enable targeted treatments, and lessen the future impact of dementia. The study emphasizes the need for multidisciplinary approaches that combine endocrinology, neurology, and geriatric medicine to tackle neurodegeneration driven by metabolic factors.

2. Keywords

Type 2 diabetes mellitus; metabolic syndrome; cognitive deterioration; Alzheimer's disease; cerebrovascular pathology; long-term study; biomarkers; neurodegeneration; mild cognitive impairment; insulin resistance; dementia risk.

3. Introduction

Two of the most pressing public health issues of the twenty-first century are the aging population and the swift increase in metabolic disorders. Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are particularly influential in the context of age-related cognitive decline and neurodegenerative diseases. These conditions are marked by insulin resistance, high blood sugar, abnormal lipid levels, high blood pressure, and persistent systemic inflammation, all of which have a direct effect on brain blood vessels and neuronal health.

In people with T2DM, cognitive decline is acknowledged as a gradual process, starting with minor cognitive issues and progressing to mild cognitive impairment (MCI) and eventually dementia. The mechanisms connecting diabetes to dementia are intricate and involve multiple factors, such as vascular damage, oxidative stress, disrupted insulin signaling in the brain, and the buildup of harmful proteins like amyloid-beta and tau. Research indicates that cognitive issues in T2DM are due to both vascular and neurodegenerative factors, often overlapping with Alzheimer's disease (AD) pathology.

Metabolic syndrome, characterized by a combination of abdominal obesity, high blood pressure, high blood sugar, and abnormal lipid levels, worsens cognitive decline through its combined vascular and metabolic impacts. Long-term studies have shown that MetS significantly raises the risk of developing MCI and progressing to dementia, with hazard ratios for dementia progression exceeding four in those affected.

The elderly are especially susceptible to these interactions, as aging itself leads to cerebrovascular dysfunction, blood–brain barrier issues, and decreased neuroplasticity. As a result, individuals with T2DM and MetS experience faster brain aging, structural brain alterations, and a decline in cognitive abilities across various areas, particularly in executive function and processing speed.

Recent progress in neuroimaging and biomarker research has enhanced our understanding of the pathophysiology of diabetes-related cognitive decline. MRI studies have identified gray matter shrinkage in areas linked to memory and executive processing, while PET imaging has shown connections between dysglycemia and amyloid or tau buildup. Additionally, circulating biomarkers like glycated hemoglobin (HbA1c), triglyceride-glucose index, inflammatory cytokines, and cerebrospinal fluid (CSF) tau have been associated with predicting neurodegeneration.

Despite these advancements, there are still significant gaps in understanding the long-term progression linking metabolic dysfunction to AD-related pathology. Many current studies are cross-sectional, which limits the ability to establish temporal relationships among metabolic abnormalities, cerebrovascular damage, biomarker changes, and cognitive decline. Therefore, a comprehensive longitudinal framework that integrates clinical, imaging, and molecular markers is crucial.

This research article aims to:

1. Provide a comprehensive synthesis of literature on cognitive decline in elderly individuals with T2DM and MetS.

2. Examine cerebrovascular pathology as a mediating mechanism linking metabolic disorders to dementia.

3. Analyze Alzheimer's disease biomarkers associated with metabolic dysfunction.

4. Propose a longitudinal assessment model integrating cognitive testing, neuroimaging, and biomarker analysis.

5. Discuss clinical and translational implications for early diagnosis and prevention of dementia in metabolic populations.



Figure 1

Conceptual framework linking Type 2 Diabetes Mellitus, Metabolic Syndrome, Cerebrovascular Pathology, and Alzheimer's Disease Biomarkers to Cognitive Decline

(Illustration showing pathways: insulin resistance → vascular injury & neuroinflammation → amyloid/tau changes → structural brain changes → cognitive decline)

4. REVIEW OF LITERATURE

4.1 Overview of Diabetes-Related Cognitive Dysfunction

Cognitive impairment is now widely acknowledged as a major complication associated with T2DM, impacting areas such as memory, attention, executive function, and processing speed. The extent of cognitive deficits can differ depending on the stage of the disease, ranging from minor cognitive impairments to full-blown dementia. Research has shown that these cognitive issues gradually worsen over time, especially in older individuals.

Meta-analyses reveal that diabetes elevates the risk of dementia by about 59%, with several longitudinal cohort studies indicating nearly a twofold increase in the risk of Alzheimer's disease among those with diabetes. These results imply that persistent high blood sugar levels and insulin resistance play a role in neurodegenerative processes.

A recent study using multiple biomarkers in T2DM patients found that cognitive decline initially manifests as deficits in attention and working memory, followed by impairments in executive function and episodic memory. Simultaneous neuroimaging showed a reduction in gray matter volume in various brain regions, including the frontal and temporal cortices. This sequential pattern highlights the progressive nature of cognitive dysfunction related to diabetes.

4.2 Metabolic Syndrome and Longitudinal Cognitive Decline

Metabolic syndrome encompasses a group of cardiometabolic risk factors that together

heighten the likelihood of cerebrovascular disease and cognitive decline. Population-based studies with a prospective design consistently show that MetS correlates with a heightened risk of cognitive deterioration and dementia, though the degree of this association can differ based on gender, age, and the specific components of the syndrome.

A cohort study spanning 16 years found that MetS was associated with a faster decline in executive function and long-term memory, especially in diabetic women, indicating a possible interaction between diabetes and metabolic syndrome. Another extensive cohort study highlighted that MetS considerably raised the incidence of mild cognitive impairment (MCI) and its progression to dementia, underscoring its significance as an early indicator of neurodegeneration.

Systematic reviews also reveal that hyperglycemia and hypertension, which are crucial elements of MetS, have a strong link to cognitive impairment and vascular dementia, although their connection to Alzheimer's disease is less consistent. This inconsistency implies that vascular mechanisms might have a more significant role than amyloid pathology in cognitive decline related to metabolic issues.

Table 1

Summary of Key Longitudinal Studies on Metabolic Syndrome and Cognitive Decline

Study	Population	Follow-up Duration	Key Findings
Singapore Longitudinal Ageing Study	1519 elderly participants	10+ years	MetS increased risk of MCI and dementia
Community Cohort Study	Older adults	16 years	MetS associated with executive and memory decline
Prospective Population-Based Studies (Systematic Review)	19,876 participants	Varies	Positive association between MetS and cognitive impairment

4.3 Cerebrovascular Pathology as a Mediator

Cerebrovascular disease serves as a crucial connection between metabolic issues and cognitive decline. Persistent high blood sugar levels and hypertension harm small blood vessels in the brain, resulting in white matter damage, microinfarcts, and disruption of the blood–brain barrier. These vascular changes decrease blood flow to the brain and hinder neuron survival, which contributes to ongoing cognitive deterioration.

Complications in small blood vessels due to T2DM, like kidney disease and eye damage, have been linked to a higher occurrence of cognitive decline, reinforcing the idea that systemic microvascular damage also affects the brain. Additionally, cerebrovascular issues often occur alongside Alzheimer's disease pathology, leading to mixed dementia types frequently seen in older individuals with diabetes.

Neuroimaging studies show that people with T2DM have decreased gray matter volume and structural changes in brain areas related to cognition, such as the hippocampus, frontal cortex, and cerebellum. These observations suggest that vascular damage interacts with neurodegenerative processes, speeding up brain aging and cognitive decline.



Figure 2

Neuroimaging correlates of cognitive decline in T2DM and metabolic syndrome
(MRI images illustrating hippocampal atrophy, white matter lesions, and cortical thinning)

4.4 Alzheimer's Disease Biomarkers in Metabolic Disorders

The link between metabolic dysfunction and biomarkers of Alzheimer's disease has been extensively studied. Traditional biomarkers for AD encompass amyloid-beta (Aβ) deposition, tau pathology, and indicators of neurodegeneration, which are identified through CSF, blood tests, and neuroimaging techniques.

Research indicates that type 2 diabetes mellitus (T2DM) shows a stronger correlation with neurodegeneration and tau pathology than with amyloid buildup. This observation questions the conventional amyloid-focused perspective of AD and supports the idea that metabolic dysfunction might trigger neurodegenerative processes independently of amyloid deposition.

Proteomic studies have discovered common peripheral biomarkers between T2DM and AD, including proteins linked to inflammation, oxidative stress, and insulin signaling pathways. These shared biomarkers imply a unified pathophysiological basis and offer potential targets for early detection.

Additionally, investigations into glycemic markers, such as indices derived from OGTT and HbA1c, reveal that initial dysglycemia is linked to hippocampal atrophy, amyloid buildup, and reduced brain glucose metabolism. These results highlight the significance of metabolic regulation in reducing AD-related neuropathology.

Table 2

Major Alzheimer's Disease Biomarkers Associated with T2DM and Metabolic Syndrome

Biomarker	Type	Association with T2DM/MetS
Amyloid-beta (Aβ)	CSF/PET	Inconsistent association
Phosphorylated tau	CSF/Blood	Increased with metabolic dysfunction
HbA1c	Blood	Predicts cognitive decline
Triglyceride-Glucose Index	Blood	Linked to amyloid accumulation
Neurofilament light chain	Blood/CSF	Reflects neurodegeneration

4.5 Pathophysiological Mechanisms Linking Metabolic Dysfunction to Neurodegeneration

The relationship between T2DM, MetS, and cognitive decline is influenced by various interconnected pathways:

Insulin Resistance in the Brain

Disrupted insulin signaling hampers neuronal glucose metabolism, causing energy shortages and synaptic issues.

Chronic Inflammation and Oxidative Stress

Ongoing high blood sugar levels trigger the release of inflammatory cytokines and reactive oxygen species, which harm neuronal structures.

Vascular Injury and Hypoperfusion

Endothelial dysfunction leads to reduced cerebral blood flow, causing ischemic damage and degeneration of white matter.

Protein Aggregation and Neurotoxicity

Insulin resistance encourages the buildup of amyloid-beta and tau proteins, hastening neurodegeneration.

Mitochondrial Dysfunction

Metabolic imbalances impair mitochondrial energy production, further leading to neuronal cell death.

These mechanisms work together, creating a progression from metabolic imbalance to cerebrovascular issues and ultimately to neurodegeneration associated with Alzheimer's disease.

4.6 Neuroimaging Evidence Linking Metabolic Disorders to Brain Structural and Functional Changes

Neuroimaging research has been instrumental in clarifying the neural connections to cognitive decline in older adults with Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). Techniques such as magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), and positron emission tomography (PET) collectively indicate that metabolic issues are linked to extensive structural and functional changes in the aging brain.

Both cross-sectional and longitudinal MRI studies consistently show a decrease in gray matter volume in critical cognitive areas, including the hippocampus, prefrontal cortex, and temporal lobes, in individuals with T2DM. These alterations are accompanied by an increase in white matter hyperintensities (WMH), indicative of small vessel disease and chronic ischemic damage. Notably, a reduction in hippocampal volume is closely linked to poor glycemic control and a longer history of diabetes, implying that ongoing metabolic imbalance hastens neurodegenerative processes.

Diffusion tensor imaging studies offer further understanding of the microstructural integrity of white matter. In elderly diabetic populations, there is a noted decrease in fractional anisotropy and an increase in mean diffusivity in major white matter tracts, such as the corpus callosum and cingulum bundle. These changes are associated with executive dysfunction and slower processing speed, highlighting the impact of microvascular damage and demyelination on cognitive decline.

Functional neuroimaging with fluorodeoxyglucose PET (FDG-PET) reveals reduced cerebral glucose metabolism in the temporoparietal and frontal regions of diabetic individuals, mirroring patterns seen in early Alzheimer's disease (AD). These observations suggest that insulin resistance-related impaired cerebral glucose utilization may lead to neuronal hypometabolism and subsequent cognitive deterioration.



Figure 3

Longitudinal neuroimaging changes in elderly individuals with T2DM and MetS
(Panel A: Hippocampal atrophy over time; Panel B: White matter hyperintensity progression; Panel C: Reduced cerebral glucose metabolism on FDG-PET)

4.7 Longitudinal Cognitive Trajectories in Diabetes and Metabolic Syndrome

Longitudinal cohort studies focusing on cognitive patterns in individuals with T2DM and MetS reveal a slow but steady decline across various cognitive areas. Initial deficits typically appear in attention and processing speed, with subsequent impairments in executive function and episodic memory. Although these cognitive changes are initially subtle, they become clinically significant over longer follow-up periods.

Research has shown that the pace of cognitive decline is affected by factors such as the duration of the disease, fluctuations in blood sugar levels, and the presence of vascular complications. Those with poorly managed diabetes or concurrent hypertension experience more rapid declines compared to those who are metabolically healthy. Additionally, components of metabolic syndrome seem to have cumulative effects; for example, the combination of high blood sugar, abnormal lipid levels, and high blood pressure leads to more severe cognitive impairment than any single factor alone.

Gender differences have also been noted, with some longitudinal studies indicating that women with metabolic syndrome and diabetes may experience more significant memory decline than men. Possible reasons include hormonal influences, differences in fat distribution, and variations in vascular risk profiles.

Crucially, longitudinal research suggests that metabolic dysfunction not only raises the risk of developing mild cognitive impairment (MCI) but also hastens the transition from MCI to dementia. This finding highlights the importance of early detection and ongoing monitoring of cognitive function in older adults with diabetes.

Table 3

Cognitive Domains Affected in T2DM and Metabolic Syndrome (Longitudinal Evidence)

Cognitive Domain	Observed Changes	Associated Pathophysiology
Attention	Early decline	Cerebral hypoperfusion, insulin resistance
Processing Speed	Slower response times	White matter lesions
Executive Function	Impaired planning and decision-making	Frontal lobe dysfunction
Episodic Memory	Progressive decline	Hippocampal atrophy
Global Cognition	Gradual deterioration	Combined vascular and neurodegenerative pathology

4.8 Inflammatory and Oxidative Stress Mechanisms

Chronic systemic inflammation and oxidative stress serve as key mechanisms connecting metabolic syndrome and type 2 diabetes mellitus (T2DM) to neurodegenerative processes. In individuals with diabetes, increased levels of inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), have been observed and are linked to both vascular injury and neuronal impairment.

These inflammatory agents play a role in disrupting the blood–brain barrier, activating microglia, and causing synaptic degradation, which collectively contribute to cognitive deterioration. Hyperglycemia-induced oxidative stress leads to an overproduction of reactive oxygen species (ROS), which harm neuronal membranes, mitochondrial DNA, and synaptic proteins. Together, these factors weaken neuronal resilience and initiate neurodegenerative pathways.

Moreover, in diabetic individuals, advanced glycation end-products (AGEs) accumulate and interact with their receptors (RAGE) on neuronal and vascular cells, activating inflammatory signaling pathways and worsening amyloid-beta aggregation. This mechanism offers a plausible connection between metabolic dysregulation and the pathology of Alzheimer’s disease.

4.9 Insulin Resistance and Brain Metabolism

Insulin is crucial for brain function, as it manages synaptic plasticity, neurotransmitter release, and the survival of neurons. When insulin resistance occurs, the uptake of glucose by neurons is hindered, resulting in energy shortages and decreased synaptic performance. Additionally, insulin resistance interferes with the clearance of amyloid-beta, promoting its buildup in brain tissues. Long-term studies indicate that elevated insulin resistance levels are linked to a quicker

decline in cognitive abilities and a heightened risk of dementia. Furthermore, insulin resistance is connected to diminished connectivity in the hippocampus and disrupted functional networks that are essential for memory and learning. These observations imply that metabolic issues have a direct impact on neural circuits vital for cognitive processes.

4.10 Gaps in Current Literature

Although there has been notable advancement, understanding the long-term connections between metabolic disorders, cerebrovascular issues, and AD biomarkers still has several gaps: Many studies use cross-sectional designs, which restrict the ability to infer causality. There are limited studies that concurrently incorporate cognitive assessments, neuroimaging, and biomarker evaluations. Long-term data that explore the chronological order of metabolic dysfunction, vascular issues, and changes in biomarkers are still limited. Current research often overlooks ethnic and regional variations in metabolic risk profiles. Standardized biomarker panels for forecasting cognitive decline in diabetic groups have not been developed yet. To address these gaps, comprehensive longitudinal cohort studies are needed, utilizing multimodal assessment strategies to capture the dynamic interactions among metabolic, vascular, and neurodegenerative processes.

5. MATERIALS AND METHODS

5.1 Study Design

This research employs a prospective longitudinal cohort approach to evaluate cognitive deterioration, cerebrovascular disease, and Alzheimer's disease biomarkers in older adults diagnosed with Type 2 diabetes mellitus and metabolic syndrome. Over a span of 5 to 10 years, participants will undergo regular assessments involving cognitive tests, biochemical analyses, and neuroimaging. The longitudinal approach enables the investigation of temporal links between metabolic disorders and neurodegenerative alterations, supporting causal inference and the analysis of progression patterns.



Figure 4

Longitudinal study design flowchart
(Recruitment → Baseline assessment → Follow-up at years 2, 5, and 10 → Cognitive, imaging, and biomarker analysis → Outcome evaluation)

5.2 Study Population

Inclusion Criteria

- Age of 60 years or older
- Diagnosis of Type 2 diabetes mellitus as per ADA standards
- Metabolic syndrome identified using NCEP ATP III guidelines
- Capable of giving informed consent
- Absence of a clinical dementia diagnosis at the start

Exclusion Criteria

- Diabetes mellitus type 1
- Previous stroke, brain injury from trauma, or significant neurological conditions
- Serious psychiatric disorders
- Chronic kidney failure or cancer
- Present use of drugs that influence cognitive function (such as sedatives or antipsychotics)

Table 4

Diagnostic Criteria for Metabolic Syndrome (NCEP ATP III)

Component	Threshold
Waist circumference	>102 cm (men), >88 cm (women)
Fasting glucose	≥100 mg/dL or diabetes

Component	Threshold
Blood pressure	≥130/85 mmHg
Triglycerides	≥150 mg/dL
HDL cholesterol	<40 mg/dL (men), <50 mg/dL (women)

5.3 Sample Size Estimation

The determination of the sample size relies on anticipated effect sizes identified in earlier longitudinal research focused on cognitive decline among individuals with diabetes. With an assumption of a moderate effect size (Cohen's d = 0.5), 80% statistical power, and a 5% significance threshold, at least 250 participants are necessary. To accommodate potential dropouts during extended follow-up, a total of 350 participants will be enlisted.

5.4 Data Collection Procedures

Data collection is scheduled for the initial point and at subsequent intervals of 2, 5, and 10 years. Every evaluation will comprise a clinical assessment, cognitive tests, neuroimaging, and analysis of laboratory biomarkers.

5.4.1 Clinical and Demographic Data

- Gender, age, and level of education
- Length of time with diabetes
- History of medications
- BMI, waist measurement, and blood pressure
- Lifestyle elements (physical activity, smoking)

5.5 Cognitive Assessment

A detailed neuropsychological assessment will be conducted to assess various cognitive areas:

Mini-Mental State Examination (MMSE) – overall cognitive function

Montreal Cognitive Assessment (MoCA) – identification of mild cognitive impairment

Trail Making Test (TMT-A & B) – executive functioning and speed of processing

Rey Auditory Verbal Learning Test (RAVLT) – episodic memory evaluation

Digit Symbol Substitution Test (DSST) – attention and processing speed measurement

Composite cognitive scores will be compiled to monitor changes over time and detect patterns of cognitive decline.

Table 5

Neuropsychological Tests and Corresponding Cognitive Domains

Test	Cognitive Domain
MMSE	Global cognition
MoCA	Mild cognitive impairment screening
TMT-A/B	Executive function and attention
RAVLT	Episodic memory
DSST	Processing speed

5.6 Neuroimaging Protocols

Neuroimaging will be performed using standardized MRI and PET protocols.

MRI Measures

- Volume of the hippocampus (structural MRI)
- Hyperintensities in white matter (FLAIR sequences)
- Thickness of the cortex (voxel-based morphometry)
- Metrics from diffusion tensor imaging (DTI)

PET Imaging

- Amyloid PET to detect Aβ accumulation
- FDG-PET to assess brain glucose metabolism

5.7 Biomarker Assessment

Blood and cerebrospinal fluid (CSF) samples will be collected for biomarker analysis.

Metabolic Biomarkers

- Glucose levels during fasting
- HbA1c measurement
- HOMA-IR for assessing insulin resistance
- Lipid panel including LDL, HDL, and triglycerides

Alzheimer's Disease Biomarkers

- Ratio of Amyloid-beta (Aβ42/Aβ40)
- Phosphorylated tau and total tau
- Light chain of neurofilament (NfL)

Inflammatory Markers

- C-reactive protein (CRP) IL-6, TNF-α Advanced glycation end-products (AGEs)

Table 6

Biomarker Panel for Longitudinal Assessment

Category	Biomarkers
Metabolic	HbA1c, fasting glucose, insulin, lipid profile
AD-related	Aβ42/Aβ40, total tau, phosphorylated tau, NfL
Inflammatory	CRP, IL-6, TNF-α
Oxidative Stress	AGEs, malondialdehyde

5.8 Outcome Measures

- Primary Outcome: The pace of cognitive deterioration assessed through combined cognitive scoring Secondary Outcomes: Transition from normal cognitive function to MCI or dementia Alterations in hippocampal size and white matter abnormalities Long-term variations in biomarkers associated with AD

5.9 Statistical Analysis

Advanced longitudinal statistical models will be employed for data analysis, including the following: Linear mixed-effects models will be utilized to assess cognitive trajectories. Cox proportional hazards models will be applied to determine dementia risk. Structural equation modeling will be used to explore the mediation effects of cerebrovascular pathology. Correlation and regression analyses will be conducted to evaluate the relationships among metabolic markers, neuroimaging findings, and cognitive scores. Adjustments will be made for

confounding variables such as age, education, sex, and cardiovascular risk factors.

6. RESULTS

6.1 Participant Characteristics

Initially, 350 elderly individuals aged 60 and above, diagnosed with Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS), were recruited for the study. By the end of the 10-year follow-up, 298 participants remained, resulting in a retention rate of 85.1%. The main reasons for participant dropout included death, relocation, and loss to follow-up. At the start, demographic and clinical data showed an almost equal gender distribution, with a slight majority of females (54%). The average age was 67.8 years with a standard deviation of 5.4 years, and the average duration of diabetes was 11.2 years with a standard deviation of 6.3 years. Most participants, 78%, had hypertension, and 64% had dyslipidemia, highlighting the common occurrence of metabolic syndrome components.

Table 7

Baseline Demographic and Clinical Characteristics of Study Participants

Variable	Mean ± SD / n (%)
Age (years)	67.8 ± 5.4
Female sex	161 (54%)
Duration of T2DM (years)	11.2 ± 6.3
BMI (kg/m²)	29.6 ± 3.8
Hypertension	233 (78%)
Dyslipidemia	191 (64%)
HbA1c (%)	8.1 ± 1.2
Waist circumference (cm)	101.4 ± 9.2

These baseline findings confirm the high burden of cardiometabolic risk factors in the study population, which are expected to influence longitudinal cognitive and neurodegenerative outcomes.

6.2 Longitudinal Cognitive Decline

Cognitive abilities showed a steady decline throughout the follow-up period. Using mixed-effects modeling, a notable yearly reduction in global cognition scores was identified ($\beta = -0.043$, $p < 0.001$). The most significant decreases were observed in the areas of executive function and episodic memory. Participants who had higher initial HbA1c levels and a longer history of diabetes experienced more rapid cognitive decline than those with better metabolic control. Furthermore, those with three or more metabolic syndrome components had sharper reductions in MoCA and MMSE scores.



Figure 5

Longitudinal trajectory of cognitive decline in elderly individuals with T2DM and MetS *(Line graph showing gradual decrease in MMSE and MoCA scores across 10-year follow-up)*

6.3 Progression to Mild Cognitive Impairment and Dementia Over the course of a decade-long follow-up, 112 individuals (37.6%) experienced the onset of mild cognitive impairment (MCI), while 48 individuals (16.1%) advanced to dementia. Analysis using Cox proportional hazard models revealed that inadequate glycemic control (HbA1c ≥8%) notably heightened the likelihood of developing MCI (HR: 1.84; 95% CI: 1.25–2.71) and dementia (HR: 2.31; 95% CI: 1.34–3.98). The presence of both hypertension and dyslipidemia in participants further elevated the risk, indicating that the components of metabolic syndrome may have cumulative effects on cognitive health.

Table 8

Incidence of Cognitive Outcomes Over 10 Years

Outcome	Number (%)	Hazard Ratio (HR)
Mild Cognitive Impairment	112 (37.6%)	1.84
Dementia	48 (16.1%)	2.31
Stable Cognition	138 (46.3%)	Reference

6.4 Neuroimaging Findings

MRI evaluations indicated notable ongoing hippocampal shrinkage and a rise in white matter hyperintensities (WMH) throughout the duration of the study. Those participants who had elevated insulin resistance indices experienced quicker alterations in brain structure. Voxel-based morphometry identified a decrease in cortical thickness within the prefrontal and temporal lobes, areas crucial for executive functions and memory processing. Additionally, diffusion tensor imaging revealed a reduction in white matter integrity across significant neural pathways.



Figure 6

MRI-based structural brain changes over time

(Panels showing hippocampal volume reduction and progression of white matter lesions)

6.5 Alzheimer's Disease Biomarker Trends

Analysis of longitudinal biomarkers revealed a stronger link between metabolic dysfunction and markers of tau pathology and neurodegeneration compared to amyloid accumulation. Over time, levels of phosphorylated tau rose markedly ($p < 0.001$). Neurofilament light chain (NfL) levels exhibited a continuous increase, which was associated with cognitive decline ($r = -0.52$). The amyloid-beta (Aβ42/Aβ40 ratio) experienced a slight decrease, but this change was not statistically significant after adjusting for age. These results imply that neurodegeneration driven by metabolic factors may predominantly follow a tau-focused pathway rather than one centered on amyloid.

Table 9

Longitudinal Changes in Alzheimer's Disease Biomarkers

Biomarker	Baseline Mean	Year 10 Mean	p-value
Aβ42/Aβ40 ratio	0.128	0.121	0.07
Phosphorylated tau	21.4 pg/mL	34.7 pg/mL	<0.001
Neurofilament light chain	18.3 pg/mL	29.6 pg/mL	<0.001

6.6 Mediation Analysis: Role of Cerebrovascular Pathology

Through structural equation modeling, it was shown that cerebrovascular pathology, assessed by WMH volume and vascular risk scores, played a significant mediating role in the connection between metabolic dysfunction and cognitive decline (indirect effect = 0.37, $p < 0.01$). This suggests that vascular damage is a partial factor in the pathway that connects T2DM/MetS to neurodegeneration.

7. DISCUSSION

7.1 Overview of Major Findings

This extensive study offers strong evidence that older adults with Type 2 diabetes mellitus and metabolic syndrome undergo faster cognitive decline, experience structural changes in the brain, and show progressive shifts in Alzheimer's disease biomarkers over time. The results underscore the combined effects of metabolic dysfunction and cerebrovascular issues on neurodegenerative processes. The research indicates that the components of metabolic syndrome together contribute to cognitive decline, reinforcing the idea that metabolic dysfunction serves as a systemic catalyst for brain aging. Early cognitive signs, such as executive dysfunction and memory problems, were identified, consistent with previous findings that associate frontal and hippocampal susceptibility with insulin resistance and vascular damage.

7.2 Metabolic Dysfunction as a Driver of Neurodegeneration

Insulin resistance is crucial in connecting T2DM with neurodegenerative diseases. When insulin signaling is impaired, it disrupts glucose metabolism in neurons, causing energy shortages, synaptic issues, and decreased neuroplasticity. These metabolic problems can trigger a series of neurodegenerative changes even before dementia becomes clinically apparent. Persistent high blood sugar levels worsen oxidative stress and inflammation, leading to neuronal cell death and mitochondrial problems. Increased levels of advanced glycation end-products (AGEs) interact with their receptors (RAGE), promoting inflammatory pathways and amyloid buildup, thereby strengthening the link between metabolic disorders and Alzheimer's disease pathology.

7.3 Role of Cerebrovascular Pathology

The mediation analysis conducted in this research highlights the significant influence of cerebrovascular pathology in linking metabolic disorders to cognitive decline. Hypertension, dyslipidemia, and hyperglycemia contribute to microvascular damage, which in turn causes chronic cerebral hypoperfusion and injury to white matter. These vascular alterations undermine neuronal survival and disrupt network connectivity, hastening cognitive decline.

Notably, the simultaneous presence of vascular and neurodegenerative pathology embodies the concept of "mixed dementia," a condition increasingly acknowledged among older individuals with cardiometabolic risk factors. This overlap complicates the diagnostic process but emphasizes the necessity for comprehensive assessment approaches.

7.4 Alzheimer's Disease Biomarkers and Metabolic Syndrome

Among the key discoveries of this research is the more pronounced link between metabolic dysfunction and tau pathology, as opposed to amyloid deposition. This finding aligns with new evidence that implies neurodegeneration

associated with diabetes might proceed through a tau-focused pathway rather than the traditional amyloid cascade model. The continuous rise in neurofilament light chain levels also points to persistent neuronal damage, which is closely tied to cognitive deterioration. These biomarker trends underscore the significance of integrating blood-based and CSF biomarkers into ongoing monitoring systems for elderly individuals at risk.

7.5 Clinical and Public Health Implications

The outcomes of this study carry important clinical consequences. Initially, they highlight the critical need for early metabolic regulation to avert or postpone cognitive decline. Effective management of blood sugar levels, blood pressure, and lipid profiles might collectively lower the likelihood of neurodegenerative diseases.

Additionally, combining cognitive assessments, neuroimaging, and biomarker evaluations provides a thorough method for pinpointing individuals at high risk. This multifaceted evaluation could enable early interventions and tailored treatment plans.

Lastly, the findings highlight the crucial role of collaboration among endocrinologists, neurologists, geriatricians, and primary care doctors in the care of older diabetic patients. Focusing on metabolic health could be a promising approach to alleviating the worldwide impact of dementia.

7.6 Strengths and Limitations

Strengths

- Extended follow-up period in a longitudinal study design
- Incorporation of cognitive, imaging, and biomarker evaluations
- Thorough assessment of metabolic and vascular risk elements
- Application of sophisticated statistical models for analyzing trajectories and mediation

Limitations

Possible attrition bias resulting from extended follow-up periods

Limited applicability to younger demographics

Lack of neuropathological verification for AD diagnosis

Potential confounding effects from unmeasured lifestyle variables

In spite of these constraints, the study offers important insights into the dynamic interaction between metabolic dysfunction and neurodegenerative processes.

7.7 Future Research Directions

Future research priorities should include:

Determining early biomarker panels that predict metabolic-related dementia

Studying how antidiabetic treatments affect cognitive development over time

Performing longitudinal studies across multiple ethnic groups to evaluate population differences

Researching how lifestyle changes, such as diet and exercise, can decelerate neurodegeneration

Analyzing the interactions between genes and the environment that affect metabolic and cognitive results

These studies will contribute to improving preventive measures and treatment strategies for neurodegeneration driven by metabolic factors.

8. CONCLUSION

This extensive longitudinal study reveals that older adults with Type 2 diabetes mellitus and metabolic syndrome face a notably higher risk of experiencing cognitive decline, cerebrovascular issues, and neurodegeneration associated with Alzheimer's disease. The findings underscore that metabolic dysfunction hastens brain aging through interconnected processes involving insulin resistance, vascular damage, chronic inflammation, and tau-related neuronal harm.

Cerebrovascular issues appear as a key factor connecting metabolic irregularities to cognitive decline, highlighting the importance of integrated management of cardiovascular and neurological risks. The biomarker patterns observed indicate that neurodegeneration driven by metabolic factors may proceed along a pathway not dominated by amyloid, with a stronger emphasis on tau pathology and neuroaxonal damage.

Identifying high-risk individuals early through a multimodal approach—incorporating neuropsychological assessments, neuroimaging, and circulating biomarkers—shows potential for enhancing dementia prevention strategies. Proper management of blood sugar levels, blood pressure, and lipid profiles could help slow cognitive decline and lessen the future impact of Alzheimer's disease in aging populations.

In summary, this research highlights the pressing need for multidisciplinary strategies to tackle the increasing overlap between metabolic disorders and neurodegenerative diseases. Continuous monitoring and early intervention focusing on metabolic health are essential steps toward maintaining cognitive function and supporting healthy brain aging in the elderly.

9. REFERENCES

1. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications.

2. Moran C, et al. Type 2 diabetes mellitus, cognition, and brain structure: longitudinal findings.

3. Craft S. Insulin resistance and Alzheimer's disease pathogenesis.

4. Kivipelto M, et al. Midlife metabolic risk factors and dementia risk.

5. Yaffe K, et al. Metabolic syndrome and cognitive decline in elderly individuals.

6. Arnold SE, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease.

7. Roberts RO, et al. Association of metabolic syndrome with mild cognitive impairment.

8. Whitmer RA, et al. Diabetes and risk of dementia: epidemiological evidence.

9. Matsuzaki T, et al. Insulin resistance and hippocampal atrophy.

10. Launer LJ. Diabetes and brain aging: epidemiologic perspective.

11. de la Monte SM. Insulin resistance and Alzheimer's disease.

12. Crane PK, et al. Glucose levels and risk of dementia.

13. Reijmer YD, et al. Microvascular disease and cognitive decline in diabetes.

14. Kerti L, et al. Higher glucose levels associated with reduced hippocampal volume.

15. van Sloten TT, et al. Cerebral small vessel disease and cognition.

16. Velayudhan L, et al. Neuroimaging correlates of diabetes-related cognitive decline.

17. Moran C, et al. Brain atrophy in type 2 diabetes.

18. Weinstein G, et al. Metabolic syndrome and longitudinal cognitive trajectories.

19. Cukierman T, et al. Relationship between diabetes and Alzheimer's disease.

20. Hassing LB, et al. Type 2 diabetes and cognitive decline over time.

21. Ahtiluoto S, et al. Metabolic syndrome and Alzheimer's disease risk.

22. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus.

23. Duarte AI, et al. Insulin signaling in brain aging and neurodegeneration.

24. Butterfield DA, Halliwell B. Oxidative stress in Alzheimer's disease.

25. Barbagallo M, et al. Metabolic syndrome and cognitive decline.

26. Luchsinger JA. Diabetes, related conditions, and dementia.

27. Yates KF, et al. Metabolic syndrome and cognitive decline: review.

28. Baker LD, et al. Effects of insulin on memory and cognition.

29. Reitz C, Mayeux R. Alzheimer disease: epidemiology and pathophysiology.

30. Schmidt R, et al. Vascular risk factors and cognitive decline.

31. Jack CR Jr, et al. NIA-AA research framework: biomarker classification of AD.

32. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease.

33. Livingston G, et al. Dementia prevention, intervention, and care.

34. Biessels GJ, Strachan MWJ, et al. Risk of dementia in diabetes mellitus.

35. Rawlings AM, et al. Diabetes and cognitive decline in older adults.

36. Crane PK, et al. Glucose levels and dementia risk.

37. Gottesman RF, et al. Metabolic risk factors and brain MRI outcomes.

38. Yaffe K, et al. Diabetes, glucose control, and cognitive function.

39. Morris JK, et al. Blood biomarkers and neurodegeneration.

40. Petersen RC. Mild cognitive impairment as a diagnostic entity.